This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Signs That Your Trading Will Ruin Your Retirement - October 08, 2019
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
by Zacks Equity Research
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
Why Alexion is a Hot Takeover Target in the Biotech Sector
by Zacks Equity Research
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $50.88, marking a +0.26% move from the previous day.
Easy Investing Secrets to an Early Retirement - October 07, 2019
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study
by Zacks Equity Research
Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.
Why Bristol-Myers (BMY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $50.71, moving +0.98% from the previous trading session.
Nektar Stock Down on Disappointing Breast Cancer Study Data
by Zacks Equity Research
Nektar Therapeutics (NKTR) presents preliminary data on triple negative breast cancer patients from an early-stage study, which fails to impress investors.
Bristol-Myers' Opdivo Gains Positive CHMP View for New Dose
by Zacks Equity Research
Bristol-Myers (BMY) receives a positive response from the CHMP for a four-week dosing option with Opdivo as an adjuvant treatment of adult patients with melanoma.
The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Lockheed, Alphabet, Allergan and Kinder Morgan
Is Bristol-Myers Squibb (BMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Bristol-Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.
Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $50.52 in the latest trading session, marking a -0.1% move from the prior day.
Pfizer's Bavencio Gets CHMP Recommendation for First-Line RCC
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
Top Analyst Reports for Bristol-Myers Squibb, Lockheed Martin & Alphabet
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers Squibb (BMY), Lockheed Martin (LMT) and Alphabet (GOOGL).
5 Safe Bets for a Rocky Market
by Sejuti Banerjea
Here are 5 companies with proven track records.
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
by Zacks Equity Research
Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil
3 Big Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.
Stock Investors: Do You Need a Late Cycle Plan?
by Tracey Ryniec
The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.
Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
by Zacks Equity Research
Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $49.74 in the latest trading session, marking a +0.55% move from the prior day.
Novartis Announces New Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
by Zacks Equity Research
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
by Zacks Equity Research
Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.